Daclizumab
5 Topics Found
Drug Index
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use...
My husband spent seven weeks in the hospital, seriously ill. A major contributing factor is believed to be the Zinbryta he took for his M.S. Might anyone else have experienced major issues with Zinbryta? ## It is possible, it has actually been removed from the market, via a voluntary manufacturer withdrawal, due to the high number of adverse events that were occurring among those taking it. They do not explain exactly what all was included in the adverse events, so unfortunately, I cannot provide you with more information. However, if his doctors think it was due to the medication, then there is a very good chance that it did cause his illness. Zinbryta Recall Click here. How is he doing, now? ## Much better, thank you, but it was touch and go for a long time, and there is some residual...
2 REPLIES
Filed under
Zinbryta
Daclizumab
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use...
Daclizumab
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use...
NDC Database
Zinbryta 150 mg/ml Subcutaneous Injection, Solution by Abbvie ## Package Codes: 0074-0033-01 ## Active Ingredients: Daclizumab